NJCRI registers transgender liver health study with Gilead as collaborator

This week's registry activity centers on a single observational study tied to gender-affirming hormone therapy and liver health.

• The North Jersey Community Research Initiative (NJCRI) posted an observational prospective case-control study (NCT07746999) on liver health in transgender individuals, with Gilead Sciences listed as a collaborator. The study is enrolling by invitation, with an actual start date of March 15, 2025, and an estimated primary completion date of March 15, 2027.¹ Researchers aim to recruit a total of 60 participants, split evenly between transgender participants who have been on gender-affirming hormone therapy for more than 6 months and those on it for less than 6 months.¹ The study will evaluate liver function markers and use FibroScan imaging to assess liver elasticity and signs of fatty liver disease in this population, according to the record.